Dx & Vx Co., Ltd.
KKRX:1804001,982.00
KRW
-16.00
(-0.80%)
ISIN
KR7180400004
Return %
Stock
S&P 500
1Y
-7.17
14.39
3Y
-62.95
81.42
5Y
-74.39
68.62
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- Full Time Employees
- 62
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Seoul South Korea
- IPO Date
- Nov 20, 2015
- Website
- dxvx.com
- Similar Companies
- Business
- Dx & Vx Co., Ltd. is a South Korea-based biotechnology and integrated healthcare company engaged in molecular diagnostics, clinical genomics, health functional food manufacturing, and the development of next-generation biopharmaceuticals and vaccines. Founded in June 2001 and headquartered in Seoul, South Korea, the company was formerly known as MGMed Co., Ltd. and Cancer Rop Co., Ltd. before adopting the name Dx & Vx Co., Ltd. in December 2021. The company operates across multiple core business segments encompassing in vitro diagnostics, genomic profiling, consumer healthcare, contract development and manufacturing, and innovative drug discovery platforms. The company's core products and services encompass clinical genetic testing and genomic analysis services provided through the GenomeCheck platform, including GenomeCheck M non-invasive prenatal screening (NIPT) for fetal chromosomal abnormalities and GenomeCheck G chromosomal microarray analysis (CMA) for neonatal and pediatric genetic profiling; companion diagnostic solutions and in vitro diagnostic (IVD) test kits commercialized under the CLIDEX brand; healthcare functional foods, microbiome-based probiotics, postbiotics, and dietary supplements marketed under proprietary and partner brands such as Ofmom and BioD; contract development and manufacturing organization (CDMO) services for nutraceuticals and health supplements via its subsidiary Korea Biopharm Co., Ltd.; contract research (CRO), contract development (CDO), and contract sales (CSO) services for biotechnology and pharmaceutical partners; and proprietary biopharmaceutical therapeutic candidates, including OVM-200, a clinical-stage survivin-targeting peptide cancer vaccine; AVI-4015, a therapeutic candidate for dry eye disease; oral small-molecule GLP-1 receptor agonists for obesity and metabolic indications; the KRNA nucleic acid stabilization platform for ambient-temperature storage of mRNA and biologic formulations; and the Advanced Cell Penetrating Peptide (ACP) intracellular delivery platform developed by its majority-owned subsidiary Avixgen, Inc. Dx & Vx serves medical institutions, clinical laboratories, pharmaceutical enterprises, academic research organizations, and retail consumers across domestic and international markets, maintaining operational and commercial presence in South Korea, China, the United States, and Latin America. The company also maintains strategic and operational affiliations with the Coree Group. In recent corporate developments, Dx & Vx has executed multiple strategic transactions, technology transfers, and pipeline advancements to expand its global footprint. In 2025, the company signed a global co-development and licensing agreement with a U.S.-based biotechnology company for its mRNA-based cancer vaccine candidate, valued at up to 220 million USD in development milestones with additional long-term commercial sales milestones. In the same year, its subsidiary Avixgen entered into a 360 million USD out-licensing transaction with a U.S. biopharmaceutical company for its ACP drug delivery platform. The company also secured Asian development and commercial rights for the OVM-200 peptide cancer vaccine, completed Phase 1 clinical studies, and advanced the program toward Phase 2 clinical trials. Furthermore, Dx & Vx acquired global development rights to a ferritin-based nanoparticle universal coronavirus vaccine platform from Stanford University and executed material transfer agreements across Latin America to evaluate and deploy its KRNA room-temperature nucleic acid stabilization platform in regions with limited cold-chain infrastructure. In September 2026, the company appointed Yong-Gu Lee as Chief Executive Officer to direct global commercialization strategies and drive revenue expansion across key markets in China, North America, and other international jurisdictions.